New Insights into the PPARγ Agonists for the Treatment of Diabetic Nephropathy

摘要: Diabetic nephropathy (DN) is a severe complication of diabetes and serves as the leading cause chronic renal failure. In past decades, angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin II receptor blockers (ARBs) based first-line therapy can slow but cannot stop progression DN, which urgently requests innovation therapeutic strategies. Thiazolidinediones (TZDs), synthetic exogenous ligands nuclear peroxisome proliferator-activated receptor-γ (PPARγ), had been thought to be promising candidate for strengthening DN. However, adverse effects including fluid retention, cardiovascular complications, bone loss greatly limited their use in clinic. Recently, numerous novel PPARγ agonists involving endogenous selective modulators (SPPARMs) are emerging candidates next generation antidiabetic drugs instead TZDs. Due higher selectivity these on regulation antidiabetes-associated genes than that side effect-associated genes, they present fewer The review was undertaken address advancements potential newly developed dealing with diabetic kidney disease. At same time, new insights into strategies DN were fully addressed.